Description: Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.
Home Page: www.longboardpharma.com
LBPH Technical Analysis
4275 Executive Square
La Jolla,
CA
92037
United States
Phone:
619 592 9775
Officers
| Name | Title |
|---|---|
| Mr. Kevin R. Lind | Pres, CEO, Sec. & Director |
| Ms. Brandi L. Roberts CPA, M.B.A. | Chief Financial Officer |
| Mr. Chadwick J. Orevillo MPH | VP & Head of Operations |
| Megan E. Knight | Head of Investor Relations |
| Mr. Steven W. Spector J.D. | Head of Bus. Devel. & Gen. Counsel |
| Dr. Anne M. Danks | VP & Head of Preclinical Devel. |
| Dr. Jodi Parsons | VP & Head of Regulatory Affairs |
| Dr. Randall E. Kaye M.D. | Chief Medical Officer |
| Gus Cardenas | VP & Head of Quality Assurance |
| Dr. Marco Peters Ph.D. | VP & Head of Translational Science |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8508 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-03-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 21 |